Affordable Access

deepdyve-link
Publisher Website

Drug screening and development from the affinity of S protein of new coronavirus with ACE2

Authors
  • Jiang, Yue-Peng1
  • Zhao, Xiao-Xuan2
  • Lv, Hui-Qing1
  • Wen, Cheng-Ping1
  • 1 Zhejiang Chinese Medical University,
  • 2 Heilongjiang University of Chinese Medicine,
Type
Published Article
Journal
European Journal of Clinical Microbiology & Infectious Diseases
Publisher
Springer-Verlag
Publication Date
Oct 09, 2020
Pages
1–9
Identifiers
DOI: 10.1007/s10096-020-04048-7
PMID: 33034780
PMCID: PMC7545154
Source
PubMed Central
Keywords
License
Unknown

Abstract

Recently, various studies have shown that angiotensin-converting enzyme 2 (ACE2) acts as the “doorknob” that can be bound by the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which conduces to its entrance to the host cells, and plays an important role in corona virus disease 2019 (COVID-19). This paper aims to collect and sorts out the existing drugs, which exert the ability to block the binding of S protein and ACE2 so as to provide directions for the later drug development. By reviewing the existing literature, we expound the pathogenesis of SARS-CoV-2 from the perspective of S protein and ACE2 binding, and summarize the drugs and compounds that can interfere with the interaction of spike protein and ACE2 receptor from different ways. We summarized five kinds of substances, including peptide P6, griffithsin, hr2p analogs, EK1, vaccine, monoclonal antibody, cholesterol-depleting agents, and extracts from traditional Chinese medicine. They can fight SARS-CoV-2 by specifically binding to ACE2 receptor, S protein, or blocking membrane fusion between the host and virus. ACE2 is the key point for SARS-CoV-2 to enter the cells, and it is also the focus of drug intervention. Our drug summary on this pathomechanism is expected to provide ideas for the drug research on SARS-CoV-2 and help to develop anti-coronavirus drugs of broad spectrum for future epidemics.

Report this publication

Statistics

Seen <100 times